RareCyte Expands Spatial Proteomics Portfolio with New Orion Systems

The company also appoints Neil Kennedy as President to drive global growth.

Apr. 20, 2026 at 3:46pm

Got story updates? Submit your updates here. ›

A highly textured, abstract painting in soft blues, greens, and grays, featuring sweeping geometric shapes and precise botanical spirals, conceptually representing the complex structures and interactions of spatial proteomics.RareCyte's new spatial proteomics systems aim to unlock deeper insights into disease mechanisms and therapeutic targets by enabling researchers to analyze protein expression and localization within tissue samples.Seattle Today

RareCyte, a leader in precision biology products and technologies, has announced a significant expansion of its spatial proteomics portfolio with the commercial launch of the Orion HT and Orion LE systems. The company also appointed Neil Kennedy as President to accelerate the adoption of spatial proteomics in clinical and translational research.

Why it matters

Spatial proteomics, the study of proteins and their interactions within the context of tissue, is a rapidly growing field with applications in drug development and clinical research. RareCyte's new Orion systems and leadership appointment demonstrate the company's commitment to advancing this technology and making it more accessible to researchers.

The details

The Orion HT and Orion LE systems extend the Orion platform from assay development through clinical trials, backed by an expanding biomarker reagent portfolio. The new systems are designed to enable researchers to analyze protein expression and localization within tissue samples, providing valuable insights for drug development and disease research.

  • RareCyte announced the new Orion systems and leadership appointment on April 20, 2026.

The players

RareCyte

A leader in precision biology products and technologies, specializing in spatial proteomics.

Neil Kennedy

The newly appointed President of RareCyte, tasked with driving global growth and the adoption of spatial proteomics.

Got photos? Submit your photos here. ›

What they’re saying

“The expansion of the Orion platform and our growing reagent portfolio reflect RareCyte's commitment to building technologies that advance biomarker-driven clinical research and drug development.”

— Neil Kennedy, President

The takeaway

RareCyte's investment in spatial proteomics technology and leadership signals the growing importance of this field in advancing precision medicine and drug development, with the potential to unlock new insights into disease mechanisms and therapeutic targets.